AstraZeneca plc. Is the giant Anglo-Swedish pharmaceutical enterprise which has been founded since 6th of April 1999 following the amalgamation of Astra AB of Sweden and Zeneca Group plc of the Great Britain. The corporate headquarters of this new venture is situated at London, England and the research and development- R&D headquarters of the company located in Sodertalje in Sweden. However, its major R&D centers are scattered in the different countries like the United States, the United Kingdoms, Sweden and India.

Since the year 1993 Zeneca was the part of Imperial Chemical Industries-ICI before it was amalgamated. The new venture AstraZeneca is engaged in developing, producing and marketing of various pharmaceutical formulations that are widely used for treating disorders that include: gastrointestinal, cardiac & vascular, neurological, psychiatric, infections, respiratory, pathological inflammations as well as oncology sectors.

Following the amalgamative affiliation AstraZeneca has initiated during the year 2004 with the taking over of Cambridge Antibody Technology-CAT. The company is now at the concluding junctures of exercising mandatory acquirement decisions against excellent CAT shares.

Under the present CEO of AstraZeneca, David Brennan, the company, on 23rd of April, 2007, declared that MedImmune and AstraZeneca have signed the affirmative understanding according to which AstraZeneca plans to take over MedImmune in all cash transaction at USD 58 per share summing up to around 15.2 billion USD.

One of the most significant and unique move adopted by the company includes the Patient’s Assistance Program which provides medications for low income Americans through free supplies to the most eligible patients.

Some of the major products of the company include: Entocort, Losec, Nexium, Atacand, Crestor, Exanta, Accolate, Bambec, Arimidex, Casodex, Indural, Mysoline, Apatef and Merrem.